Bryan See, Carotech’s regional product manager, and W.H. Leong, vice president of sales and marketing, will share the results of human studies on the brain and liver, as well as ongoing human clinical trials.. More than a decade of research has led to a better understanding of Tocomin SupraBio’s mechanism in reducing the risk of damage from stroke-related brain injuries, and also slowing down the progress of brain aging.
A recent clinical trial, published by United Kingdom and Malaysian researchers in the American Heart Association’s journal Stroke, reported that Tocomin SupraBio supplementation attenuates the development of white latter lesions in the human brain.
Another group of researchers in Malaysia and the Philippines have independently shown in human studies that Tocomin SupraBio supplementation improves liver echogenic responses in patients with non-alcoholic fatty liver disease (NAFLD). They found lifestyle modification and exercise, together with supplementation of Tocomin SupraBio, is nearly four times more effective for improving liver stiffness in NAFLD patients, compared to lifestyle modification and exercise alone.
Researchers at the University of Florida and the University of Nebraska have recently discovered a new health benefit of tocotrienols in inhibiting adipose inflammation and attenuating high-fat diet-induced obesity, which were both in vitro and in vivo studies. This is an exciting discovery for tocotrienols in addressing obesity related conditions.